LINEO THAHANE to Anti-HIV Agents
This is a "connection" page, showing publications LINEO THAHANE has written about Anti-HIV Agents.
Connection Strength
0.732
-
Tolerability of lopinavir versus dolutegravir in children and adolescents with HIV. AIDS. 2026 May 01; 40(5):600-610.
Score: 0.186
-
HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial. J Antimicrob Chemother. 2026 Mar 04; 81(4).
Score: 0.186
-
Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis. Clin Infect Dis. 2023 01 06; 76(1):10-17.
Score: 0.149
-
Genotype-Informed Versus Empiric Management Of VirEmia (GIVE MOVE): study protocol of an open-label randomised clinical trial in children and adolescents living with HIV in Lesotho and Tanzania. BMC Infect Dis. 2020 Oct 19; 20(1):773.
Score: 0.128
-
Resistance-informed versus empirical management of viraemia in children and adolescents with HIV in Lesotho and Tanzania (GIVE MOVE trial): a multisite, open-label randomised controlled trial. Lancet Glob Health. 2024 08; 12(8):e1312-e1322.
Score: 0.042
-
Predicting mortality within 1 year of ART initiation in children and adolescents living with HIV in sub-Saharan Africa: a retrospective observational cohort study. Lancet Glob Health. 2024 06; 12(6):e929-e937.
Score: 0.041